Team:Calgary/Project/OurSensor/Reporter/BetaLactamase
From 2013.igem.org
Azzucoloto (Talk | contribs) |
Azzucoloto (Talk | contribs) |
||
Line 61: | Line 61: | ||
<p><b>Figure 6. </b>Absorbance values at 600nm for each tube at four different time points: 0, 30, 60 and 120min. The cultures that expressed beta-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> BBa_K1189007</a>) showed higher absorbance levels, showing that the cells were able to grow in the presence of ampicillin.</a>. | <p><b>Figure 6. </b>Absorbance values at 600nm for each tube at four different time points: 0, 30, 60 and 120min. The cultures that expressed beta-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> BBa_K1189007</a>) showed higher absorbance levels, showing that the cells were able to grow in the presence of ampicillin.</a>. | ||
</figcaption> | </figcaption> | ||
- | <p>In addition to that, we have purified our beta-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> BBa_K1189007</a>) and our mobile TALE linked to beta-lactamase construct (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031">BBa_K1189031</a >) (Figure 7) and we have demonstrated that beta lactamase retained its enzymatic activity for both proteins. We repeated a variation of ampicillin survival assay where we pretreated LB containing ampicillin and chloremphenicol with our purified TALE linked to beta-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031">BBa_K1189031</a >). We then cultured bacteria in the treated LB that only carry resistance to chloremphenicol. Therefore, the bacteria are only able to survive if the our isolated protein retained its enzymatic abilities. We can show that the bacteria susceptible to ampicillin was able to grow in the presence of our purified construct protein (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031">BBa_K1189031</a >), which means that we are expressing and purifying functional protein which is degrading the ampicillin (Figures 6 and 8). Figure 8 shows the OD at 24 hour time point from culturing where Figure 6 shows OD change over time. Both graphs show and increase in OD for cultures pre-treated with our protein demonstrating our protein is functional.</p> | + | <p>In addition to that, we have purified our beta-lactamase (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007">BBa_K1189007</a>) and our mobile TALE linked to beta-lactamase construct (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031">BBa_K1189031</a >) (Figure 7) and we have demonstrated that beta lactamase retained its enzymatic activity for both proteins. We repeated a variation of ampicillin survival assay where we pretreated LB containing ampicillin and chloremphenicol with our purified TALE linked to beta-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031">BBa_K1189031</a >). We then cultured bacteria in the treated LB that only carry resistance to chloremphenicol. Therefore, the bacteria are only able to survive if the our isolated protein retained its enzymatic abilities. We can show that the bacteria susceptible to ampicillin was able to grow in the presence of our purified construct protein (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031">BBa_K1189031</a >), which means that we are expressing and purifying functional protein which is degrading the ampicillin (Figures 6 and 8). Figure 8 shows the OD at 24 hour time point from culturing where Figure 6 shows OD change over time. Both graphs show and increase in OD for cultures pre-treated with our protein demonstrating our protein is functional.</p> |
<figure> | <figure> | ||
<img src="https://static.igem.org/mediawiki/2013/4/45/YYC2013_TALE_September_22_Blac.jpg"> | <img src="https://static.igem.org/mediawiki/2013/4/45/YYC2013_TALE_September_22_Blac.jpg"> | ||
<figcaption> | <figcaption> | ||
- | <p><b>Figure 7. </b>On the left crude lysate of beta-lactamase + his (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007"> BBa_K1189007</a>) from different lysis protocols: a <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/GlassBeadsCellLysisProtocolforProteinSamples">mechanical</a> and with <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/OsmoticShock">sucrose</a>, respectively. On the right, western blot of <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004">TALE A</a>-linker-beta-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031">BBa_K1189031</a>) showing that we were able to express and purify our construct. | + | <p><b>Figure 7. </b>On the left crude lysate of beta-lactamase + his (<a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189007">BBa_K1189007</a>) from different lysis protocols: a <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/GlassBeadsCellLysisProtocolforProteinSamples">mechanical</a> and with <a href="https://2013.igem.org/Team:Calgary/Notebook/Protocols/OsmoticShock">sucrose</a>, respectively. On the right, western blot of <a href="http://parts.igem.org/wiki/index.php?title=Part:BBa_K782004">TALE A</a>-linker-beta-lactamase (<a href=" http://parts.igem.org/wiki/index.php?title=Part:BBa_K1189031">BBa_K1189031</a>) showing that we were able to express and purify our construct. |
</figcaption> | </figcaption> | ||
<figure> | <figure> |
Revision as of 03:08, 28 September 2013
Beta-Lactamase
Beta-Lactamase
What is Beta-lactamase?
Beta-lactamase (BLA) is an enzyme encoded by the ampicillin resistant gene (ampr) frequently present in plasmids for selection. Structurally, beta-lactamase is a 29-kDa monomeric enzyme (Figure 1). Its enzymatic activity provides resistance to beta-lactam antibiotics such as cephamysin, carbapenems and penicillium through hydrolysis of the β-lactam ring, a structure shared by these antibiotics (Qureshi, 2007).
Many advantages come from working with beta-lactamase. It shows high catalytic efficiency and simple kinetics. Also, no orthologs of BLA are known to be encoded by eukaryotic cells and no toxicity was identified making this protein very useful in studies involved eukaryotes (Qureshi, 2007). Beta-lactamase has been used to track pathogens in infected murine models (Kong et. al, 2010). However, in addition to its application in eukaryotic cells, beta-lactamase efficiently cleaves a wide variety of substrates but its versatility goes beyond that; BLA preserves its activity even when fused to heterologous protein (Moore et. al, 1997). This feature, in particular, makes beta-lactamase a potential tool for assemble of synthetic constructs.
How is Beta-lactamase used as a Reporter?
Beta-lactamase, in the presence of different substrates, can give various outputs. It can produce a fluorogenic output in the presence of a cephalosporin derivative (CCF2/AM) and BLA enzymatic activity can be detected by a fluorometer (Remy et al., 2007).
Besides fluorescence assays, beta-lactamase can also be used to obtain colourimetric outputs by breaking down synthetic compounds such as nitrocefin (Figure 2). The colour change goes from red to yellow (Remy et al., 2007). Colourimetric assays can also be done with benzylpenicillin as the substrate, which, gives a pH output that can be detected with pH indicators to give a colourimetric output (Li et al., 2008).